Trials / Recruiting
RecruitingNCT07065630
Response-Adaptive Treatment in Untreated Locoregional HPV-Negative Head and Neck Cancer
A Phase II Study of Volrustomig, Paclitaxel, and Carboplatin Followed by Response-Adaptive Treatment in Untreated Locoregional HPV-Negative Head and Neck Cancer
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 38 (estimated)
- Sponsor
- University of Chicago · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess the objective response rate following neoadjuvant therapy with volrustomig, paclitaxel, and carboplatin in previously untreated human papillomavirus (HPV)-negative locally advanced head and neck squamous cell carcinoma .
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Volrustomig | 500mg or 750mg (cycles 1-2) and 250mg thereafter IV day 1. |
| DRUG | Carboplatin | 100mg/m2 IV day 1 and day 8. |
| DRUG | Paclitaxel | AUC 5 IV day 1 |
Timeline
- Start date
- 2025-10-07
- Primary completion
- 2029-08-13
- Completion
- 2029-08-13
- First posted
- 2025-07-15
- Last updated
- 2026-03-04
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07065630. Inclusion in this directory is not an endorsement.